1stOncology™: Cancer Intelligence Service – Page 14768 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Altimmune to Present at the 29th Annual Piper Jaffray Conference

On November 21, 2017 Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, reported that Bill Enright, president and chief executive officer of Altimmune, will present a corporate overview at the 29th Annual Piper Jaffray Conference, taking place November 28-29, 2017 in New York, NY (Press release, Altimmune, NOV 21, 2017, View Source [SID1234522185]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Presentation Details:
Date: November 28, 2017
Time: 2:00pm Eastern Standard Time
Location: Lotte New York Palace Hotel; New York, NY

Myovant Sciences to Participate in the Evercore ISI BioPharma Catalyst / Deep Dive Conference

On November 21, 2017 Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and endocrine diseases, reported that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences and Frank Karbe, Chief Financial Officer of Myovant Sciences, will participate in a fireside chat at the Evercore ISI BioPharma Catalyst / Deep Dive Conference in Boston, Massachusetts on November 29, 2017 at 2:00 p.m. ET (Press release, Myovant Sciences, NOV 21, 2017, http://investors.myovant.com/news-releases/2017/11-21-2017-133121676 [SID1234522225]).

The event will be webcast live and may be accessed via the Events page under the Investors and Media section of Myovant’s website at www.myovant.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 30 days following the conference.

Constellation Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

On November 21, 2017 Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, reported that President and Chief Executive Officer Jigar Raythatha will present a company overview at the 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017 at 8:50 a.m. EST. The conference is being held November 28-29, 2017 at the Lotte New York Palace in New York, NY (Press release, Constellation Pharmaceuticals, NOV 21, 2017, View Source [SID1234522223]).

Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

On November 21, 2017 Cancer Prevention Pharmaceuticals (CPP), a clinical stage biotechnology company, reported it will give a corporate presentation at the Piper Jaffray 29th Annual Healthcare Conference on November 28, 7:50-8:10 a.m. ET at the Lotte New York Palace in New York City (Track Seven: Kennedy 2, 4th floor) (Press release, Cancer Prevention Pharmaceuticals, NOV 21, 2017, http://canprevent.com/wp-content/uploads/2013/08/CPP-Piper-Jaffray-Conference-FINAL-2017-11-21.pdf [SID1234522220]). CPP CEO Jeff Jacob will give an update on the company’s pipeline including its lead Phase 3 drug CPP-1X/sul for treatment of familial adenomatous polyposis (FAP). CPP recently engaged Piper Jaffray to support its anticipated financing activities.

FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. In June, an Independent Data Monitoring Committee (IDMC) recommended continuation of the Phase 3 trial following a planned interim futility analysis. In September, the U.S. Food and Drug Administration granted CPP-1X/sul "fast track" status, potentially speeding regulatory approval and commercialization.

In 2016 CPP signed a collaboration agreement with Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) that grants Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sul in North America. Sucampo recently highlighted CPP-1X/sul during their 2017 R&D Day in New York City.

For more information on the FAP clinical trial (CPP FAP-310), please visit: View Source

Genomic Health to Present at the 29th Annual Piper Jaffray Healthcare Conference

On November 21, 2017 Genomic Health, Inc. (NASDAQ: GHDX) reported that it will present at the 29th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 28, 2017 at 10:30 a.m. Eastern Time (Press release, Genomic Health, NOV 21, 2017, View Source [SID1234522219]).

To access the live and subsequently archived webcast of the presentation, go to the Investor Relations section of the company’s web site at View Source Please connect to the web site at least 15 minutes prior to the presentation to allow for any software download that may be necessary. An archived replay will be available for three months beginning 24 hours after the live presentation.